The Dxcover Platform enables rapid development of liquid biopsies for detection of cancer and other diseases.
To date, Dxcover has raised £5.1million in total, through investment from Scottish Enterprise, Norcliffe Capital Limited, Mercia Asset Management, the University of Strathclyde, Eos Advisory, SIS Ventures, and our Founders.
With the Dxcover Platform diagnosing disease is as simple as Drop Dry Detect.
Dxcover Limited owns all the IP and has patents granted in the USA, Europe, and China for the detection of all types of cancer.
Huge market potential
Cancer is the fastest growing segment of the in vitro diagnostics market, with a predicted 43% increase in diagnosis rates by 2035 and a massive demand for new and innovative diagnostics tools.
A preliminary health economic assessment covering Europe and the USA indicates that the Dxcover liquid biopsy test will be highly attractive to both government health service providers and commercial laboratories, bringing significant cost savings to both.